$2.25-0.08 (-3.43%)
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
NextCure, Inc. in the Healthcare sector is trading at $2.25 with a market capitalization of $22M. Wall Street consensus targets $19.33 (3 analysts), implying a +759.3% move over the next 12 months. The stock is currently near its 52-week low of $2.17, remaining 77.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$10.11Mβ | -$9.76Mβ | -$8.95Mβ | -$27.29Mβ | -$11.62M |
| Net Income | -$9.80Mβ | -$9.44Mβ | -$8.62Mβ | -$26.81Mβ | -$10.98M |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that i...
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The SIM0505 employs a unique epitope which enhances tumour binding.